Abstract
Depression, the most prevalent psychiatric disorder, has a lifelong risk of 20% and is related to high rates of death among the patients. Thus, this study aims to conduct a systematic review of changes in executive functions of adult patients diagnosed with depression. We found 1381 articles; however, only 28 were selected and recovered. The inclusion criteria was the assessment of executive functions with at least one neuropsychological test, and articles that evaluated primarily adult individuals with depression, without comparison to other psychiatric disorders. Although most of the studies (25 out of 28 analyzed) have shown deficits in some executive subcomponents, these findings are not conclusive because they used different parameters of assessment. Moreover, many variables were not controlled, such as the different subtypes of the disorder, the high level of severity, comorbidity and the use of drugs. Most studies showed different deficits in executive functions in depressed patients, but further longitudinal studies are needed in order to confirm these findings.
Keywords: Cognitive impairment, depression, drugs, executive functions, neuropsychological assessment, psychiatric disorders.
CNS & Neurological Disorders - Drug Targets
Title:Executive Function Impairments in Patients with Depression
Volume: 13 Issue: 6
Author(s): Mariana R.P. Alves, Tetsuya Yamamoto, Oscar Arias-Carrion, Nuno B.F. Rocha, Antonio E. Nardi, Sergio Machado and Adriana Cardoso
Affiliation:
Keywords: Cognitive impairment, depression, drugs, executive functions, neuropsychological assessment, psychiatric disorders.
Abstract: Depression, the most prevalent psychiatric disorder, has a lifelong risk of 20% and is related to high rates of death among the patients. Thus, this study aims to conduct a systematic review of changes in executive functions of adult patients diagnosed with depression. We found 1381 articles; however, only 28 were selected and recovered. The inclusion criteria was the assessment of executive functions with at least one neuropsychological test, and articles that evaluated primarily adult individuals with depression, without comparison to other psychiatric disorders. Although most of the studies (25 out of 28 analyzed) have shown deficits in some executive subcomponents, these findings are not conclusive because they used different parameters of assessment. Moreover, many variables were not controlled, such as the different subtypes of the disorder, the high level of severity, comorbidity and the use of drugs. Most studies showed different deficits in executive functions in depressed patients, but further longitudinal studies are needed in order to confirm these findings.
Export Options
About this article
Cite this article as:
Alves R.P. Mariana, Yamamoto Tetsuya, Arias-Carrion Oscar, Rocha B.F. Nuno, Nardi E. Antonio, Machado Sergio and Cardoso Adriana, Executive Function Impairments in Patients with Depression, CNS & Neurological Disorders - Drug Targets 2014; 13 (6) . https://dx.doi.org/10.2174/1871527313666140612102321
DOI https://dx.doi.org/10.2174/1871527313666140612102321 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Overview of Experimental and Conventional Pharmacological Approaches in the Treatment of Sleep and Wake Disorders
Current Topics in Medicinal Chemistry Intranasal Fluorescent Nanocrystals for Longitudinal <i>In Vivo</i> Evaluation of Cerebral Microlesions
Pharmaceutical Nanotechnology Is there a Role for Bevacizumab in Non-Glial Tumors?
Current Drug Targets Nanotechnologies: A Strategy to Overcome Blood-Brain Barrier
Current Drug Metabolism Post-Panning Computer-Aided Analysis of Phagotope Collections Selected with Neurocysticercosis Patient Polyclonal Antibodies Separation of Disease-Relevant and Irrelevant Peptide Sequences
Combinatorial Chemistry & High Throughput Screening Reflection on Existence of Neural and Non-Neural Pathway for Nose- to- Brain Using a Novel Formulation of an Anticholinesterase Piperidine Derivative
Current Nanoscience Pediatric Chronic Daily Headache
Current Pediatric Reviews Recent Advances in Neuromyelitis Optica Spectrum Disorder: Pathogenesis, Mechanisms and Potential Treatments
Current Pharmaceutical Design Entry of Oximes into the Brain: A Review
Current Medicinal Chemistry Nanosized Drug Delivery Systems for Direct Nose to Brain Targeting: A Review
Recent Patents on Drug Delivery & Formulation "Neuro-Semeiotics" and "Free-Energy Minimization" Suggest a Unified Perspective for Integrative Brain Actions: Focus on Receptor Heteromers and Roamer Type of Volume Transmission
Current Protein & Peptide Science Cerebrovascular and Blood-Brain Barrier Morphology in Spontaneously Hypertensive Rats: Effect of Treatment with Choline Alphoscerate
CNS & Neurological Disorders - Drug Targets Progression of Alzheimer-type Neurofibrillary Tangles is Related to the Proximodistal Segments of the Hemispheric Arteries
Current Alzheimer Research Novel Agents in CNS Myeloma Treatment
Central Nervous System Agents in Medicinal Chemistry Personalized Nanoparticles for Cancer Therapy: A Call for Greater Precision
Anti-Cancer Agents in Medicinal Chemistry Delivery of Neurotherapeutics Across the Blood Brain Barrier in Stroke
Current Pharmaceutical Design Antiepileptic Drugs for Preventing Seizures in Patients with Chronic Subdural Hematoma
Current Pharmaceutical Design Clinical Presentations and Diagnosis of Brucellosis
Recent Patents on Anti-Infective Drug Discovery Clearance of Amyloid-β Peptide Across the Blood-Brain Barrier: Implication for Therapies in Alzheimers Disease
CNS & Neurological Disorders - Drug Targets Targeted Blood-to-Brain Drug Delivery – 10 Key Development Criteria
Current Pharmaceutical Biotechnology